Key Points
- Insider sale: Amylyx Pharmaceuticals insider Gina Mazzariello sold 9,536 shares for approximately $309,539 to cover tax withholding tied to vested equity awards, reducing her holdings by 4.76% to 190,838 shares.
- Stock and earnings: AMLX opened at $33.64, up 6.4%, with a $3.75 billion market capitalization. The company reported a quarterly loss of $0.39 per share, missing analyst expectations of a $0.36 loss.
- Investor sentiment: Institutional investors own 95.84% of the stock, while analysts maintain a consensus “Buy” rating and an average price target of $36.50.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Gina Mazzariello sold 9,536 shares of the firm's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.46, for a total transaction of $309,538.56. Following the transaction, the insider directly owned 190,838 shares in the company, valued at $6,194,601.48. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Gina Mazzariello also recently made the following trade(s):
- On Thursday, July 9th, Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00.
Amylyx Pharmaceuticals Stock Up 6.4%
Shares of NASDAQ AMLX opened at $33.64 on Tuesday. The company has a market capitalization of $3.75 billion, a PE ratio of -23.52 and a beta of -0.13. The stock's 50 day moving average price is $26.01 and its 200-day moving average price is $19.00. Amylyx Pharmaceuticals, Inc. has a twelve month low of $10.83 and a twelve month high of $41.14.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). As a group, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.
Institutional Investors Weigh In On Amylyx Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth about $158,534,000. Jupiter Topco LLC purchased a new position in Amylyx Pharmaceuticals during the second quarter valued at approximately $94,014,000. Commodore Capital LP increased its holdings in Amylyx Pharmaceuticals by 38.6% during the 4th quarter. Commodore Capital LP now owns 5,650,000 shares of the company's stock worth $68,252,000 after acquiring an additional 1,574,522 shares during the period. California State Teachers Retirement System increased its holdings in Amylyx Pharmaceuticals by 2,106.9% during the 2nd quarter. California State Teachers Retirement System now owns 1,434,501 shares of the company's stock worth $25,764,000 after acquiring an additional 1,369,499 shares during the period. Finally, Siren L.L.C. purchased a new stake in Amylyx Pharmaceuticals in the 1st quarter worth approximately $17,097,000. 95.84% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the company. Citigroup raised their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. HC Wainwright boosted their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. Mizuho increased their price target on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an "outperform" rating in a research report on Tuesday, August 18th. Guggenheim raised their price objective on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a "buy" rating in a report on Thursday, August 27th. Finally, Wolfe Research raised shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $36.50.
Get Our Latest Stock Analysis on Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Company Profile
(
Get Free Report)
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
